Apnimed Inc

APMD

Valor de mercado US$ 739 mi

CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on October 1, 2026, the compensation committee of Apnimed's board of directors granted 19 new non-executive employees non-qualified stock options to purchase an aggregate of 481,300 shares of the Company's common stock under Apnimed's 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $22.54, which is equal to Apnimed's closing trading price on the grant date. One-fourth of the shares underlying each of the employee's stock options will vest on the first anniversary of each employee's start date and in equal monthly installments thereafter for the next three years, subject to such employee's continued employment with the Company on such vesting dates.

Apnimed, Inc. (APMD) is a late-stage, de-risked regulatory play with a fully funded path to commercialisation, focused on AD109 for obstructive sleep apnea (OSA). AD109 (Oxnimbi) demonstrated robust Phase 3 efficacy, clear differentiation from CPAP, and manageable safety, with an NDA under FDA review and a February 2027 PDUFA date. APMD's financials show a transition from R&D to pre-commercial buildout, with a strong cash position and multiple years of runway to support launch activities.

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update.

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on August 31, 2026, the compensation committee of Apnimed's board of directors granted 10 new non-executive employees non-qualified stock options to purchase an aggregate of 428,428 shares of the Company's common stock under Apnimed's 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $26.85, which is equal to Apnimed's closing trading price on September 1, 2026. One-fourth of the shares underlying each of the employee's stock options will vest on the first anniversary of each employee's start date and in equal monthly installments thereafter for the next three years, subject to such employee's continued employment with the Company on such vesting dates.

Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), Apnimed's sole asset and an oral therapy for obstructive sleep apnea (OSA).

The Nasdaq debut of Apnimed (NASDAQ:APMD) has given public investors their first pure-play bet on a pill for obstructive sleep apnea (OSA).

The U.S. IPO market cooled in July following the record-shattering June. The month saw seven new issuers raise $3.0 billion in proceeds, a significant slowdown from the 19 deals and $97.9 billion priced in June that was skewed by the unprecedented SpaceX IPO. Looking at the six-month IPO backlog, 10 new issuers filed in July, bringing the total pipeline to 75 companies seeking to raise $3.2 billion in aggregate proceeds.

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share.